NCT06569212 Beta-1 Adrenergic Inhibition to Reduce Cardiac Injury and Inflammation After Subarachnoid Hemorrhage (BADCATS)
| NCT ID | NCT06569212 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Madeleine Puissant |
| Condition | Non-Traumatic Subarachnoid Hemorrhage |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2024-09-23 |
| Primary Completion | 2026-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 20 participants in total. It began in 2024-09-23 with a primary completion date of 2026-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To determine the effect of early metoprolol administration after non-traumatic subarachnoid hemorrhage (SAH).
Eligibility Criteria
Inclusion Criteria: * \>18 years of age * Neuro-imaging confirmed non-traumatic subarachnoid hemorrhage Exclusion Criteria: * Traumatic cause of subarachnoid hemorrhage (e.g. fall, motor vehicle accident, other blunt trauma) as this is a different mechanism of hemorrhage. * Other forms of traumatic or non-traumatic intracranial bleed including intracerebral hemorrhage (ICH), subdural hemorrhage, epidural hemorrhage * Pregnancy (as the study medication, metoprolol, has FDA Pregnancy Category C rating) * Unstable vital signs not amenable to beta-1 adrenergic receptor inhibitor (B1ARi) administration including: * Systolic blood pressure \< 80 mmHg not stabilized on vasopressor medications * Heart rate \< 50 bpm associated with hypotension * Patients requiring vasopressor agents due to hypotension (SBP \<80 mmHg) * Other vital sign exclusion at the discretion of the treatment team * Previous history of severe heart failure (Stage C or D Heart Failure and/or NYHA Class III or IV) * Patient or legally authorized representative unwilling to provide informed consent
Contact & Investigator
Madeleine Puissant, MD, PhD
PRINCIPAL INVESTIGATOR
MaineHealth
Frequently Asked Questions
Who can join the NCT06569212 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Non-Traumatic Subarachnoid Hemorrhage. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06569212 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06569212 currently recruiting?
Yes, NCT06569212 is actively recruiting participants. Contact the research team at Madeleine.Puissant@mainehealth.org for enrollment information.
Where is the NCT06569212 trial being conducted?
This trial is being conducted at Portland, United States.
Who is sponsoring the NCT06569212 clinical trial?
NCT06569212 is sponsored by Madeleine Puissant. The principal investigator is Madeleine Puissant, MD, PhD at MaineHealth. The trial plans to enroll 20 participants.